The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Acq - P2P | Acquired



About Ventritex

Ventritex is marketed as a minimally invasive diagnostic system for mapping arrhythmias, potentially fatal or life debilitating heart rhythms.

Ventritex Headquarter Location

10065 Red Run Blvd.

Minneapolis, Minnesota, 21117,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Ventritex News

St. Jude, the No. St. Jude to Purchase Ventritex, Other Units for $660 Million - latimes

Feb 5, 2014

St. Jude to Purchase Ventritex, Other Units for $660 Million Acquisitions: Moves are part of a plan to expand its market beyond heart valves. October 24, 1996 |From Times Wire Services St. Jude Medical Inc. will pay about $660 million in stock and cash for Ventritex Inc. of Sunnyvale, Calif., and other acquisitions, expanding its share of the market for devices that treat irregular heartbeats. 1 maker of mechanical heart valves, will pay about $505 million in stock for Ventritex, a maker of defibrillators, which slow a patient's heartbeat. The St. Paul, Minn.-based company will also acquire Pacific Dunlop Ltd.'s Teletronics and Medtel units for $130 million in cash and pay $25 million for intellectual property rights from Sulzer's Intermedics. The moves, which put St. Jude in a market with an annual growth rate of 20% to 25%, are part of its plan to expand beyond heart valves--a maturing business that still generates lots of cash. "St. Jude will have its hands full trying to make this work," said Michael Weinstein, a J.P. Morgan Securities analyst. "Assuming they can, it will raise the company's long-term growth rate. " In the Ventritex acquisition, that company's stockholders will receive 0.6 share of St. Jude Medical for each of their shares. The ratio isn't dependent on St. Jude's stock price. The transaction values Ventritex at $505 million based on Tuesday's closing prices. Ventritex will purchase as many as 200,000 of its own shares before the transaction closes, which is expected later this year or in early 1997. President and Chief Executive Frank Fischer will remain with the company. Ventritex shares rose .9375 to $21.5625 on Nasdaq. St. Jude fell $1.25 to $37.375, also on Nasdaq. Ventritex has lost the technological lead it once had in the defibrillator market. Rivals Medtronic and Guidant Corp. beat it to market with defibrillators small enough to be implanted on the chest instead of the abdomen. Such implants reduce the time needed for surgery to implant the device as well as recovery time. Both Medtronic and Guidant have gained market share at Ventritex's expense as a result. To be sure, St. Jude's acquisition of Ventritex could change that trend, analysts said. "This will make Ventritex a more powerful contender," said Rachael Scherer, a Dain Bosworth analyst. Analysts said they expect the acquisition to dilute St. Jude's earnings next year and possibly in 1998. The company declined to comment on any earnings impact. "The magnitude depends on how fast things happen," said Steve Wilson, St. Jude's chief financial officer. "Both Ventritex and Teletronics are losing money but are well-positioned and poised to do better. The question is how far they bounce back and how soon. " Teletronics ran into problems last year, when two types of pacemaker wires broke inside the chests of several heart patients, prompting several lawsuits. In its purchase, St. Jude didn't take on the legal liabilities associated with those lead wires. Teletronics is close to getting government approval for several new pacemaker products that are based on a different type of sensor than existing Pacesetter products, St. Jude's Wilson said. The products are rate-responsive, which would allow a heart patient to exercise and briefly raise his heart rate without prompting a response from the pacemaker. The Teletronics agreement also includes a provision for additional payments of as much as $40 million to Pacific Dunlop over six years if certain sales milestones are met. St. Jude will also acquire some intellectual property rights from Intermedics Inc., a Freeport, Texas, unit of SulzerMedica Inc., for $25 million. That agreement includes the settlement of disputes between Intermedics and Ventritex. Wilson said the company is confident that the agreements mean St. Jude won't be sued by Medtronic or Guidant for patent violations. "The intellectual property was key," he said. "We have taken steps to ensure we will be in all markets. " FEATURED

  • Where is Ventritex's headquarters?

    Ventritex's headquarters is located at 10065 Red Run Blvd., Minneapolis.

  • What is Ventritex's latest funding round?

    Ventritex's latest funding round is Acq - P2P.

  • Who are the investors of Ventritex?

    Investors of Ventritex include St. Jude Medical, U.S. Venture Partners, InterWest Partners, MedVenture Associates, Sanderling Ventures and 4 more.

  • Who are Ventritex's competitors?

    Competitors of Ventritex include Vertos Medical, Spineology, NinePoint Medical, Endotronix, Atria Medical and 13 more.

You May Also Like

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.

Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.

Cardious Logo

Cardious is a medical device company organized to develop and commercialize the AvA Aortic Valve Bypass Graft System for use as a minimally invasive, beating heart alternative to traditional aortic valve replacement therapy.

Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.


Urovalve, Inc. has developed and patented technology to control fluid flow through small diameter flexible tubing. The core technology for the Surinate bladder management system is comprised of a magnetically controlled valve that can be activated remotely by a Surinate wearer who uses a hand held magnet to self-regulate flow. Currently available devices require continuous bladder drainage or insertion of a tube into the urethra several times each day. The Surinate bladder management system aims to provide a solution to the problems of life style, urinary tract infections, and substantial healthcare worker expenses associated with existing catheters.

Spinal Restoration

Spinal Restoration restores patients' lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop and gain regulatory approval of the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain, based on solid scientific and clinical evidence.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.